Tirzepatide dosing charts on TikTok: what's actually safe to know

What did @lifeofsamii actually say?

Straightforwardly: nothing about tirzepatide. The transcript is a motivational speech about ignoring distractions, embracing struggle, and taking action toward your goals. There are no dosing charts discussed, no clinical claims made, and no medical information delivered verbally. The caption references tirzepatide dosing charts and a "research only company page," but the spoken content is entirely unrelated to GLP-1 medications.

This matters because 150,000 people watched a video captioned with tirzepatide dosing information, tagged with compounding pharmacy and weight loss hashtags, while the actual audio contains zero medical content. Whatever charts appeared on screen, we cannot fact-check images we cannot see. What we can assess is the framing, and it deserves scrutiny.

Does the science back this up?

There is no scientific claim to evaluate from the transcript itself. However, the video's context raises real concerns worth addressing. Tirzepatide, a dual GIP and GLP-1 receptor agonist, does have an established clinical dosing protocol from the SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine), which studied doses of 5 mg, 10 mg, and 15 mg weekly for obesity treatment.

Compounded tirzepatide, which is what the hashtags suggest this content targets, is a separate regulatory matter. The FDA has not approved any compounded version of tirzepatide. In 2024, the FDA placed tirzepatide on its drug shortage list, which temporarily allowed certain compounding, but the agency has since updated its shortage determinations. Dosing charts sourced from a "research only" vendor website carry no clinical authority and may not reflect the titration schedules used in supervised medical practice.

What did they get wrong (or right)?

The creator got the disclaimer right, technically. "I'm not a doctor" is disclosed in the caption. But a disclaimer does not neutralize the potential harm of spreading unverified dosing information to 150,000 viewers, many of whom are presumably seeking weight loss medication guidance.

What is wrong, or at least deeply incomplete, is the sourcing. A "research only company page" is not a peer-reviewed source, a clinical guideline, or a licensed prescriber. Research chemicals sold under that label are not FDA-approved for human use. Presenting their dosing parameters as a practical reference for people using or considering compounded tirzepatide is misleading by framing, even if the charts themselves were never verbally described.

The motivational audio layered over medication content also creates a specific kind of persuasive packaging: urgency, action, self-determination. That framing, paired with weight loss hashtags, functions as encouragement to self-direct a medication regimen. That combination is worth naming plainly.

What should you actually know?

Tirzepatide's clinical dosing, as studied in SURMOUNT-1 and SURPASS trials, follows a structured titration starting at 2.5 mg weekly, escalating every four weeks under physician supervision. Side effect management, particularly nausea and gastrointestinal symptoms, is part of why that titration matters. Skipping steps or using a dosing chart from an unverified source can increase adverse event risk.

Compounded tirzepatide is not the same product as FDA-approved Zepbound or Mounjaro. The FDA has explicitly warned consumers that compounded drugs have not been reviewed for safety, efficacy, or quality. If you are considering any GLP-1 medication, the appropriate path runs through a licensed prescriber who can review your medical history, not through a TikTok caption and a vendor chart.

The "research only" label is a regulatory workaround some peptide vendors use to sell substances not approved for human use. It does not mean the product is safe. It means the seller is attempting to limit liability.

Bottom line

This video does not contain any spoken medical claims to fact-check. The transcript is motivational content. But the packaging, caption, hashtags, and implied visual content point toward tirzepatide dosing guidance sourced from an unregulated vendor. That framing misleads viewers about what constitutes reliable medical information. A popular TikTok caption is not a prescription. A research-chemical vendor's chart is not clinical guidance. If you are using or considering compounded tirzepatide, work with a licensed provider on a monitored titration plan.